L-carnosine for Schizophrenia
Completed · Not applicable · Has a placebo group
Conditions studied: Schizophrenia, Schizoaffective Disorder
In brief
The investigators' hypothesis is that oral L-carnosine treatment (as compared with placebo) will enhance cognitive abilities (specifically: measures of attention, executive function, working memory, visuospatial ability and language) in persons with schizophrenia or schizoaffective disorder. Secondarily, they hypothesize that there will be secondary improvements in positive, negative and mood symptoms with L-carnosine treatment. The investigators aim to test these hypotheses by conducting a randomized, placebo controlled, add-on treatment trial of L-carnosine (added to existing antipsychotic treatment) up to 84 recruited subjects with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) schizophrenia/schizoaffective disorder for a period of 16 weeks. Measures of cognition and psychopathology will be utilized for evaluating primary and secondary outcomes, along with safety assessments.
Key facts
- Study ID
- NCT00177177
- Run by
- University of Pittsburgh
- People needed
- 84
- Starts
- 2004-03-01
- Expected to finish
- 2007-12-01
- Last updated by the study team
- 2013-01-16
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- DSM-IV-TR diagnosis of schizophrenia (any subtype, except currently catatonic) or schizoaffective disorder
- Ages 18 to 65 years
- Men or women
- Ability to read and communicate in English
- 8th grade education or greater
- Ability to provide informed, competent and written consent
- Current antipsychotic medication is stable for greater than or equal to 4 weeks.
You may not qualify if…
- Medically unstable conditions
- Known allergy to L-carnosine
- Current cognitive decline is attributable to a diagnosis of dementia or other neurological disorder
- Pregnant or lactating women
- Mini-mental state examination score (MMSE) less than or equal to 23
- HIV positive status resulting in AIDS-related dementia.
Where it is running
- Mayview State Hospital — Bridgeville, Pennsylvania, United States
- Dubois Regional Medical Center — DuBois, Pennsylvania, United States
- Mon-Yough Community Services, Inc. — McKeesport, Pennsylvania, United States
- Western Psychiatric Institute and Clinic — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.